Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance
Big Pharmas — as well as more than a few biotechs — are on the hunt for the best, cutting-edge gene editing tech available, and today we can tell you about Sanofi’s choice.
The Paris-based giant’s head of oncology research and its chief of genomic medicine have settled on Scribe Therapeutics’ CasX editing tech for their work on NK cells. And the deal with the Jennifer Doudna spinout comes with a $25 million get-to-know-you upfront and a cool $1 billion in biobuck milestones, provided they can neatly knock down all the pins in the deal.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.